Subscribe
Halawi / Shutterstock.com
8 October 2024NewsEuropeMarisa Woutersen

Astellas defends blockbuster cancer treatment patent

A UK court upholds the patent for Astellas Pharma's life-extending prostate cancer treatment | Judgment dismisses attempts by Accord Healthcare, Sandoz, and Teva to invalidate the patent | Parallel litigation in Germany and Netherlands ongoing.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Pfizer sues Chinese pharma firm over prostate cancer drug
6 August 2024   Big pharma subsidiary and Japanese collaborator allege infringement of blockbuster drug product | $1.2 billion treatment developed by University of California.
Big Pharma
US refuses to compel lower prices for Pfizer and Astellas cancer drug
23 March 2023   NIH rejects petition to use “march-in” rights to allow cheaper competition | Xtandi is “widely available” to public, federal agency says.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Pfizer sues Chinese pharma firm over prostate cancer drug
6 August 2024   Big pharma subsidiary and Japanese collaborator allege infringement of blockbuster drug product | $1.2 billion treatment developed by University of California.
Big Pharma
US refuses to compel lower prices for Pfizer and Astellas cancer drug
23 March 2023   NIH rejects petition to use “march-in” rights to allow cheaper competition | Xtandi is “widely available” to public, federal agency says.

More on this story

Americas
Pfizer sues Chinese pharma firm over prostate cancer drug
6 August 2024   Big pharma subsidiary and Japanese collaborator allege infringement of blockbuster drug product | $1.2 billion treatment developed by University of California.
Big Pharma
US refuses to compel lower prices for Pfizer and Astellas cancer drug
23 March 2023   NIH rejects petition to use “march-in” rights to allow cheaper competition | Xtandi is “widely available” to public, federal agency says.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott